Elevated Hemoglobin/Hematocrit in Smoldering Multiple Myeloma: A Paradoxical Finding Requiring Vigilance
Elevated hemoglobin and hematocrit in a patient with smoldering multiple myeloma (SMM) is atypical and warrants investigation for secondary causes, as SMM typically presents with normal or declining hemoglobin; however, this finding significantly increases thrombotic risk and mandates aggressive thromboprophylaxis if the patient requires any treatment.
Understanding the Clinical Context
SMM is characterized by asymptomatic disease with ≥10% bone marrow plasma cells and/or serum M-protein ≥3 g/dL without end-organ damage 1. A progressive decrease in hemoglobin is actually the most frequent and reliable indicator of progression to active myeloma 1. Therefore, elevated hemoglobin/hematocrit represents an unusual presentation that requires careful evaluation.
Immediate Diagnostic Considerations
When encountering elevated hemoglobin/hematocrit in SMM, you must:
- Exclude secondary polycythemia by checking erythropoietin levels, oxygen saturation, and evaluating for sleep apnea, chronic lung disease, or renal pathology that could stimulate erythropoiesis 1
- Rule out polycythemia vera through JAK2 mutation testing, as this represents a distinct myeloproliferative disorder that can coexist with plasma cell disorders 1
- Assess for dehydration or hemoconcentration through clinical examination and basic metabolic panel 1
Critical Thrombotic Risk Assessment
The combination of SMM and elevated hemoglobin/hematocrit creates a substantially elevated thrombotic risk that requires immediate attention:
Baseline Thrombotic Risk in Multiple Myeloma
- Patients with multiple myeloma have a baseline risk of 3%-4% for venous thrombotic events 2
- This risk is significantly enhanced by specific therapeutic agents, particularly immunomodulatory drugs (IMiDs) like thalidomide and lenalidomide 2
Compounding Risk Factors
Multiple factors increase thrombotic risk in this population 2:
- High-dose dexamethasone therapy
- Cytotoxic chemotherapy (doxorubicin)
- Reduced mobility from neurological complications or bone pain
- Concurrent use of erythropoiesis-stimulating agents (ESAs)
- Prior personal or family history of thrombotic events
- Elevated hemoglobin/hematocrit itself
Management Strategy for SMM with Elevated Hemoglobin
If Patient Does NOT Require Treatment (Standard SMM Management)
Most patients with SMM should be observed without treatment 1, 3, 4:
- Follow every 3 months during the first year to establish pattern of evolution (evolving vs. non-evolving type) 1
- Monitor CBC, serum creatinine, calcium, albumin, hemoglobin, and M-protein levels 1
- Patients should not be treated until progressive disease with end-organ damage is evident 1, 4
- In this scenario, the elevated hemoglobin/hematocrit should be managed as a separate medical issue (treat underlying cause if identified, consider phlebotomy if significantly elevated to reduce thrombotic risk)
If Patient DOES Require Treatment (High-Risk SMM or Progression)
If treatment is indicated based on high-risk features or progression, thromboprophylaxis is mandatory 2:
Thromboprophylaxis Algorithm
- For patients with 0-1 individual risk factors: Aspirin 100 mg daily 2
- For patients with ≥2 risk factors OR receiving high-dose dexamethasone/multiagent chemotherapy: Full-dose anticoagulation with low molecular weight heparin (LMWH) or full-dose warfarin 2
- Sub-therapeutic doses of anticoagulants (such as small doses of warfarin) are NOT recommended 2
Additional Risk Factors to Count
- Elevated hemoglobin/hematocrit (present in your patient)
- IMiD therapy (lenalidomide/thalidomide)
- High-dose dexamethasone
- Prior thrombosis
- Reduced mobility
- Concurrent ESA use (which should be avoided given already elevated hemoglobin)
Critical Pitfall: Erythropoiesis-Stimulating Agents
Never use ESAs in a patient with elevated hemoglobin/hematocrit 5, 6:
- ESAs should only be initiated when hemoglobin falls below 10 g/dL 5, 6
- Target hemoglobin with ESA therapy is 10-12 g/dL, never exceeding 12 g/dL 5, 6
- Hemoglobin above 14 g/dL increases thromboembolic complications and hypertension 2
- ESAs increase relative risk of thromboembolic events by 67% (RR 1.67; 95% CI: 1.35-2.06) 6
When to Initiate Treatment for SMM
High-risk SMM patients may benefit from early intervention 3, 7:
- High-risk criteria include: ≥10% bone marrow plasma cells AND M-protein ≥3 g/dL, plus ≥95% phenotypically aberrant plasma cells, or immunoparesis, or evolving type 1, 3
- Treatment with lenalidomide and dexamethasone in high-risk SMM has shown improved time to progression and overall survival 3, 7
- However, given elevated hemoglobin/hematocrit, this patient would require full-dose anticoagulation (LMWH or warfarin) if lenalidomide is used 2
Monitoring Strategy
For Observation Approach
- CBC every 3 months for first year, then adjust based on stability 1
- Monitor for signs of progression: declining hemoglobin (paradoxically, in this case), rising calcium, rising creatinine, new bone lesions 1
- Full re-evaluation (bone marrow, skeletal survey) only when reasonable suspicion of progression 1
For Treatment Approach
- More frequent monitoring given thrombotic risk
- Assess for thrombotic symptoms at each visit
- Consider hemoglobin reduction strategies (phlebotomy) if persistently elevated while on IMiD therapy